CagrilintideDosage, Side Effects & Legal Status
Cagrilintide is an investigational amylin analogue, not an approved weight-loss medicine in the US. Its best human evidence is a 26-week Phase 2 trial, not the vial-based dosing charts or combination protocols sold online.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Long-acting amylin analogue under clinical investigation for weight management · also sold as AM833, long-acting amylin analogue
Photo: Jorge Alberto Vega Barrera / UnsplashThe studies behind the headline.
Results are reported as published. A result in one population does not establish a benefit in another.
| Study | Population | Observed result | Limit |
|---|---|---|---|
| Lau et al., Lancet Phase 2 | 706 adults with overweight or obesity, without diabetes, across 57 sites | At week 26, mean weight reduction was 6.0% to 10.8% across cagrilintide doses, versus 3.0% with placebo. | 26 weeks is not evidence for indefinite use, purchased-vial quality, or combinations. |
| Lau et al., adverse-event data | Same Phase 2 population | Gastrointestinal adverse events occurred in 41% to 63% of cagrilintide groups versus 32% with placebo. | Reported rates come from a monitored trial, not a self-selected online-user population. |
Cagrilintide and retatrutide are not substitutes
Cagrilintide is an amylin analogue. Retatrutide targets GIP, GLP-1, and glucagon receptors. Their trial designs, outcomes, and adverse-event profiles cannot be combined into one dosing chart.
Compare the retatrutide trial evidenceWhat the literature and self-reports actually say.
| What's cited | Range |
|---|---|
| Phase 2 dose-finding arms | 0.3 to 4.5 mg, subcutaneous, once weekly |
| Dose escalation in the Phase 2 study | Up to 6 weeks before the maintenance dose |
| Human dose for a purchased research vial | Not established |
The figures below are study arms, included to describe what researchers tested. They are not a dosing schedule for weight loss. The Phase 2 trial used once-weekly cagrilintide with an escalation period; it did not test vendor reconstitution instructions, syringe units, or unsupervised combinations.
Signal strength, not just a list.
How often each effect shows up in the available sources, and how solid that evidence actually is.
| Signal | Frequency | Context |
|---|---|---|
| Gastrointestinal adverse events | commonly reported | 41% to 63% across cagrilintide groups versus 32% with placebo in the 26-week Phase 2 trial; nausea was the most frequent event. |
| Nausea, constipation, or diarrhoea | commonly reported | Reported in the Phase 2 trial and should not be reduced to a generic 'GLP-1 side effect' label because cagrilintide is an amylin analogue. |
| Long-term safety outside a trial | unknown / not studied | The cited pivotal evidence was 26 weeks in a controlled research population, not long-term self-administration. |
Not FDA-approved as a standalone medicine in the US.
Cagrilintide has been studied in controlled obesity trials, including as a component of investigational combination programs. Trial status and trial dosing do not establish a marketed product, a compounded-product standard, or a safe protocol for a purchased vial. Check FDA and the active trial record before relying on a claim of approval or availability.
Every claim above, traced back.
Primary studies, reviews, regulatory pages, and trial registries. Click through and check them yourself.
Cagrilintide questions, answered.
No. Cagrilintide has been investigated in clinical trials, but an investigational trial product is not the same thing as an FDA-approved medicine or a validated compounded preparation.
A 26-week Phase 2 trial tested 0.3 to 4.5 mg once weekly with dose escalation. That describes the study design; it is not a recommendation for using a research-vendor vial.
Among 706 participants, mean weight reduction ranged from 6.0% to 10.8% across cagrilintide doses at 26 weeks, versus 3.0% with placebo. Gastrointestinal adverse events occurred in 41% to 63% of cagrilintide participants versus 32% with placebo.
Keep researching.
This is a preview of the Cagrilintide report.
Create your account to check any peptide against the full research base.